Key Takeaways
- Independent pharmacies owned by L-1 pharmacists qualify on prescription revenue
- Drug inventory, dispensing systems, and working capital all eligible
- Pharmacy benefit manager (PBM) reimbursement cycles create structural capital needs
- SBA closed to L-1 holders — Bankable is the primary alternative for pharmacy funding
- Decisions in 48 hours, $100K to $3M
Independent pharmacy ownership requires a pharmacy license holder — and many L-1 holders in the pharmaceutical space are licensed pharmacists transferred from international chains or pharmaceutical company US operations. An L-1A pharmacy director who obtains a US pharmacist license and acquires an independent pharmacy is running a business with $1.5M-$4M in annual prescription revenue, a Medicare Part D PBM contract, and a regular customer base that needs their medications monthly.
The capital challenge in independent pharmacy is the PBM reimbursement cycle. The pharmacy dispenses medications, submits the claim to the PBM (CVS Caremark, Express Scripts, OptumRx), and waits 14-28 days for reimbursement. Meanwhile, drug inventory must be purchased from McKesson, AmerisourceBergen, or Cardinal Health on net-7 to net-14 terms. The gap between paying the drug distributor and receiving PBM reimbursement is structural and requires working capital.
Pharmacy Capital for L-1 Holders
- Drug inventory purchasing: Maintain sufficient inventory depth across formulary drugs — $200K-$500K in inventory for a mid-size independent pharmacy
- Automated dispensing robots: Parata, ScriptPro, or BD dispensing automation at $30K-$120K significantly increases throughput
- Pharmacy management software: QS/1, PioneerRx, or Liberty Software subscriptions and implementation
- PBM reimbursement gap bridging: Working capital to pay drug distributors before PBM reimbursement arrives
- Pharmacy acquisition: Purchasing an existing independent pharmacy from a retiring owner typically involves goodwill and inventory purchase
Check your Bankability Score or call (786) 443-5511.
Frequently Asked Questions
Yes. A licensed pharmacist on an L-1 visa who owns a US-registered independent pharmacy qualifies for Bankable funding based on prescription revenue. The pharmacist's license must be from the state where the pharmacy operates.
PBM reimbursement cycles create 14-28 day gaps between dispensing medications and receiving payment. Bankable provides working capital specifically to bridge this gap — you draw to pay drug distributors and repay when PBM reimbursements arrive.
Yes. Drug inventory is a primary capital need for independent pharmacies. A revolving inventory line lets you maintain adequate stock depth without depleting operating cash on every distributor invoice.
Bankable provides working capital for pharmacy operations. Pharmacy acquisition financing typically involves valuing the business including goodwill, and may involve a combination of our working capital products and specialized pharmacy acquisition lenders.
Six months of bank statements, PBM remittance reports (showing reimbursement rates), and prescription volume data. PBM remittance reports clearly document revenue quality and margins.
Specialty pharmacies (oncology, rheumatology, rare disease) have higher-margin reimbursements and are a growing segment. L-1 holders with clinical pharmacy backgrounds in these specialties are particularly strong profiles.
Compound pharmacy operations — preparing customized medications — qualify as pharmacy revenue if performed in an FDA-registered compound pharmacy facility. Compounding revenue is evaluated alongside standard prescription revenue.
Rural independent pharmacies often have less PBM network competition and may qualify for 340B drug pricing programs that improve margins. These factors are positive in underwriting and can offset lower absolute volume.